University of Pennsylvania Abramson Cancer Center researchers conducted a study to assess just how nimble are oncologists to FDA safety alerts. The study found that once the FDA moved to restrict the label of two immunotherapies, usage by oncologists dropped by 50%....
TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.
159 WEST BROADWAY SUITE 200 SALT LAKE CITY, UT 84101
Pin It on Pinterest